Catalogue Advanced Search

Search by Category
Search by Format
Sort By
Search by Type
Search by Category
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Contains 6 Component(s), Includes Credits

    The lecture describes the role of T2 inflammation in the transition from recurrent wheezing to childhood asthma, asthma exacerbations and treatment response. The impact of early life exposures is discussed in depth. Several case studies guide de leaner for understanding personalized decisions in pediatric asthma.

    The lecture describes the role of T2 inflammation in the transition from recurrent wheezing to childhood asthma, asthma exacerbations and treatment response. The impact of early life exposures is discussed in depth. Several case studies guide de leaner for understanding personalized decisions in pediatric asthma.

    James Gern

    Professor

    University of Wisconsin

  • Contains 6 Component(s), Includes Credits

    The lecture provides an in depth description of the allergen-specific and general type 2 immune response with tissue and blood eosinophilia, excessive and bad mucus production, tissue remodeling, barrier disfunction, microbial dysbiosis, the role of key cytokines (IL4, IL13, IL5, IL9, TSLP, IL33, IL25). The origins of the T2 response are also discussed, together with the environmental impact. At the end practical examples on how to measure barrier dysfunction are described.

     

    The lecture provides an in depth description of the allergen-specific and general type 2 immune response with tissue and blood eosinophilia, excessive and bad mucus production, tissue remodeling, barrier disfunction, microbial dysbiosis, the role of key cytokines (IL4, IL13, IL5, IL9, TSLP, IL33, IL25). The origins of the T2 response are also discussed, together with the environmental impact. At the end practical examples on how to measure barrier dysfunction are described. 

    Cezmi Akdis

    Professor

    SIAF

  • Contains 6 Component(s), Includes Credits

    The lecture describes the two types of chronic rhinosinusitis, with and without nasal polyps, linking its pathogenesis(the complex interplay between the immune-inflammatory response, epithelial barrier defect, mucus and coagulation abnormalities and microbiome) to biomarkers guiding treatment decisions.

    The lecture describes the two types of chronic rhinosinusitis, with and without nasal polyps, linking its pathogenesis(the complex interplay between the immune-inflammatory response, epithelial barrier defect, mucus and coagulation abnormalities and microbiome) to biomarkers guiding treatment decisions. The inflammatory heterogeneity in CRS impact on clinical phenotypes and disease severity is discussed in depth and is exemplified nicely with clinical cases. 

    Whitney Stevens

    Professor

    Northwestern University

  • Contains 6 Component(s), Includes Credits

    The lecture describes the two major types of gastro-intestinal inflammatory diseases, IgE and non-IgE, with a special focus on eosinophilic esophagitis, gastritis and colitis. The role of IL 13, IL-5, eotaxin, integrins, epithelial derived cytokines, innate lymphoid cells, genetic defects and environmental insults is discussed in depth in association with personalized treatment approaches. Case reports guide the learner in differentiating the atopic and non-atopic phenotypes of eosinophilic esophagitis.

    The lecture describes the two major types of gastro-intestinal inflammatory diseases, IgE and non-IgE, with a special focus on eosinophilic esophagitis, gastritis and colitis. The role of IL 13, IL-5, eotaxin, integrins, epithelial derived cytokines, innate lymphoid cells, genetic defects and environmental insults is discussed in depth in association with personalized treatment approaches. Case reports guide the learner in differentiating the atopic and non-atopic phenotypes of eosinophilic esophagitis. 

    Kari Nadeau

    Professor

    Stanford University

  • Contains 6 Component(s), Includes Credits

    The lecture provides an exhaustive description of diagnostic, monitoring, response, predictive and prognostic biomarkers for the T2 immune response, with indications when and how to use in clinical practice followed by an illustrative case report on the value of T2 biomarkers for a non-response to biological intervention in severe asthma.

    The lecture provides an exhaustive description of diagnostic, monitoring, response, predictive and prognostic biomarkers for the T2 immune response, with indications when and how to use in clinical practice followed by an illustrative case report on the value of T2 biomarkers for a non-response to biological intervention in severe asthma. 

    Manali Mukherjee

    Professor

    McMaster University

  • Contains 1 Component(s)

    Understand the state of omics science specific to asthma and allergic diseases with the current and potential applicability of omics in clinical disease prediction, treatment, and management.

    Understand the state of omics science specific to asthma and allergic diseases with the current and potential applicability of omics in clinical disease prediction, treatment, and management.

  • Contains 1 Component(s)

    Understand the state of omics science specific to asthma and allergic diseases with the current and potential applicability of omics in clinical disease prediction, treatment, and management.

    Understand the state of omics science specific to asthma and allergic diseases with the current and potential applicability of omics in clinical disease prediction, treatment, and management.

  • Contains 4 Component(s)

    This is a non-promotional, non-CME disease state educational webcast brought to you by EAACI in collaboration with and paid for by GlaxoSmithKline

    OVERVIEW

    This is a non-promotional, non-CME disease state educational webcast brought to you by EAACI in collaboration with and paid for by GlaxoSmithKline

    This webcast is a 4-part series. The topics focus on HES pathophysiology, HES diagnosis and differential diagnosis, HES complications, and HES multidisciplinary assessment.  HES is a heterogeneous group of rare disorders characterised by blood hypereosinophilia, organ dysfunction or damage attributable to tissue hypereosinophilia. The speakers will provide detail on the pathophysiology of HES, with an overview of the causes and variants of HES; discuss how to investigate HES and differentiate it from other diseases; highlight the complications, signs and symptoms that may be associated with HES; and provide clinical insight on the importance of a multidisciplinary approach for personalised assessment and treatment for patients with HES.

     

    EDUCATIONAL OUTCOME/OBJECTIVES

    To gain an understanding and clinical insight into:

    • the pathogenic role of eosinophils in HES, the mechanisms resulting in eosinophil expansion and the pathogenic contribution of other cells/mediators to HES
    • the diagnosis of HES and identifying the cause, how to rule out other disease when diagnosing HES and identify current markers for HES variants
    • the broad spectrum of complications associated with HES, and understand the importance of monitoring organs at risk, variability of complications in different disease variants and the nature of the complication in patients with HES
    • improving communication between the primary care physician and specialists and understanding why efficient multidisciplinary patient monitoring and treatment is needed.
  • Contains 1 Component(s)

    An in-depth, interactive e-learning resource aimed at improving the diagnosis and management of T2 diseases as long-term conditions for children and adults. This first educational module focuses on the T2 complex endotype and aims to define and understand the pathogenesis of T2 immune-inflammatory response, its biomarkers and visible properties, adapted to specialized care (specialists in allergy and clinical immunology, pneumology, ENT, dermatology, paediatrics).

    An in-depth, interactive e-learning resource aimed at improving the diagnosis and management of T2 diseases as long-term conditions for children and adults.

    This first educational module focuses on the T2 complex endotype and aims to define and understand the pathogenesis of T2 immune-inflammatory response, its biomarkers and visible properties, adapted to specialized care (specialists in allergy and clinical immunology, pneumology, ENT, dermatology, paediatrics). 

    The module unfolds in three stages:

    AVAILABLE NOW: Purchase the T2 module/s of your choice via myeaaci.org or education.eaaci.org. This includes outstanding lectures on different aspects of T2 Diseases including clinical case studies, instrumental to better understand the disease and implement their teachings within your clinical practice. Please note that in order to access these platforms you need to have an EAACI account. You can always open your account free of charge.

    AVAILABLE  STARTING IN APRIL: Purchase an add-on to your module, and take part in a Live Q&A session with the key opinion leaders. This is your opportunity to ask questions and dive deeper into the topic of your choice. The live Q&A will then be recorded, for you to watch at any convenient time. You will be able to e-mail the speaker with any further questions in written form.

    AVAILABLE IN JUNE: Purchase an add-on to your module, take a short multiple-choice assessment, and you will be able to get CME Accreditation from the knowledge you have gained. 



    Marek Jutel (Moderator)

    Professor

    Ioana Agache (Moderator)

    Professor

  • Contains 11 Component(s)

    Food allergy can result in considerable morbidity, impact negatively on quality of life, and prove costly in terms of medical care. It is mostly IgE-mediated and a chronic disease affecting up to 4% of the European population.

    Food allergy can result in considerable morbidity, impact negatively on quality of life, and prove costly in terms of medical care. It is mostly IgE-mediated and a chronic disease affecting up to 4% of the European population.

    This eLearning product delves into the epidemiology and economics; the needs, perspectives and best practices for food allergic patients; allergens and their detection; the role of the skin barrier and skin manifestations of food allergy; latest updates in diagnosis and management; and the immune processes in the disease.

    Get eLearning! Gain a deeper knowledge of food allergy and anaphylaxis by completing one or more of EAACI’s courses on this topic.

    To learn about important aspects for helping patients understand food allergy diagnosis and management, including:

    - To help set the patient perspective regarding diagnosis through consideration of the needs of patients and anticipated issues, with a clinical focus on how to approach and support the adolescent patient.

    - To learn how to develop a food challenge protocol for different age groups and for different type of food challenges

    - To learn about nutritional components with immunomodulatory effects and their impact on threshold levels in oral food challenge tests and on disease severity in adult eosinophilic esophagitis patients

    Jennifer Gerdts

    The patients viewpoint on getting a good diagnosis

    Graham Roberts

    Supporting adolescents at risk of anaphylaxis

    Daisy Luiten

    Dietary composition in peanut allergic children is related to threshold levels in oral food challenge tests

    Sanne Wielders

    Dietary composition in adult eosinophilic esophagitis patients is related to disease severity

    Carina Venter

    Oral food challenges – the dieticians perspective